IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis

IMU Biosciences is a biotechnology company that uses a simple blood sample to measure over 100 million immune data points by combining high-fidelity multi-omic analysis with proprietary machine learning analytics. The platform is designed to enable disease diagnosis, monitor treatment progression, and predict treatment suitability for individual patients.